AU2019309757A1 - Tumor reduction formulations and methods of use thereof - Google Patents

Tumor reduction formulations and methods of use thereof Download PDF

Info

Publication number
AU2019309757A1
AU2019309757A1 AU2019309757A AU2019309757A AU2019309757A1 AU 2019309757 A1 AU2019309757 A1 AU 2019309757A1 AU 2019309757 A AU2019309757 A AU 2019309757A AU 2019309757 A AU2019309757 A AU 2019309757A AU 2019309757 A1 AU2019309757 A1 AU 2019309757A1
Authority
AU
Australia
Prior art keywords
composition
tumor
acid
agent
cancer
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Abandoned
Application number
AU2019309757A
Other languages
English (en)
Inventor
Steven Hoffman
John Rothman
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Tyme Inc
Original Assignee
Tyme Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Tyme Inc filed Critical Tyme Inc
Publication of AU2019309757A1 publication Critical patent/AU2019309757A1/en
Abandoned legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/075—Ethers or acetals
    • A61K31/08—Ethers or acetals acyclic, e.g. paraformaldehyde
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/16—Amides, e.g. hydroxamic acids
    • A61K31/165—Amides, e.g. hydroxamic acids having aromatic rings, e.g. colchicine, atenolol, progabide
    • A61K31/167—Amides, e.g. hydroxamic acids having aromatic rings, e.g. colchicine, atenolol, progabide having the nitrogen of a carboxamide group directly attached to the aromatic ring, e.g. lidocaine, paracetamol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
    • A61K31/4015—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil having oxo groups directly attached to the heterocyclic ring, e.g. piracetam, ethosuximide
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
    • A61K31/575—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids substituted in position 17 beta by a chain of three or more carbon atoms, e.g. cholane, cholestane, ergosterol, sitosterol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
    • A61K47/10—Alcohols; Phenols; Salts thereof, e.g. glycerol; Polyethylene glycols [PEG]; Poloxamers; PEG/POE alkyl ethers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/22—Heterocyclic compounds, e.g. ascorbic acid, tocopherol or pyrrolidones
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/28—Steroids, e.g. cholesterol, bile acids or glycyrrhetinic acid

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Epidemiology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Engineering & Computer Science (AREA)
  • Oil, Petroleum & Natural Gas (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Pain & Pain Management (AREA)
  • Dermatology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Medicinal Preparation (AREA)
AU2019309757A 2018-07-09 2019-07-02 Tumor reduction formulations and methods of use thereof Abandoned AU2019309757A1 (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201862695613P 2018-07-09 2018-07-09
US62/695,613 2018-07-09
PCT/US2019/040264 WO2020023191A1 (en) 2018-07-09 2019-07-02 Tumor reduction formulations and methods of use thereof

Publications (1)

Publication Number Publication Date
AU2019309757A1 true AU2019309757A1 (en) 2021-03-04

Family

ID=75267393

Family Applications (1)

Application Number Title Priority Date Filing Date
AU2019309757A Abandoned AU2019309757A1 (en) 2018-07-09 2019-07-02 Tumor reduction formulations and methods of use thereof

Country Status (11)

Country Link
EP (1) EP3820482A4 (de)
JP (1) JP2021530482A (de)
KR (1) KR20220098082A (de)
CN (1) CN112584841A (de)
AU (1) AU2019309757A1 (de)
BR (1) BR112021000279A8 (de)
CA (1) CA3105717A1 (de)
EA (1) EA202190201A1 (de)
IL (1) IL280000A (de)
PH (1) PH12021550033A1 (de)
WO (1) WO2020023191A1 (de)

Families Citing this family (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA3140042A1 (en) 2019-05-14 2020-11-19 Tyme, Inc. Compositions and methods for treating cancer
IL293706A (en) * 2019-12-09 2022-08-01 Tyme Inc Pharmacy preparations and methods
US10905698B1 (en) 2020-05-14 2021-02-02 Tyme, Inc. Methods of treating SARS-COV-2 infections

Family Cites Families (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
KR20060135729A (ko) * 2004-01-29 2006-12-29 백스터 인터내셔널 인코포레이티드 중추신경계 전달 증가를 위한 항레트로바이러스제의나노현탁액
WO2006099685A1 (en) * 2005-03-24 2006-09-28 Medical Therapies Limited Method for the prophylaxis or treatment of carcinomas
CN101023940A (zh) * 2006-02-20 2007-08-29 郝守祝 一种紫杉烷类化合物的药用组合物、制备方法及用途
AU2015287749B2 (en) * 2014-07-11 2021-03-11 The Regents Of The University Of California Tumor selective macropinocytosis-dependent rapidly internalizing antibodies
US9687528B2 (en) * 2014-12-23 2017-06-27 Steven Hoffman Transdermal formulations
AU2017232348A1 (en) * 2016-03-15 2018-09-06 Tyme, Inc. Pharmaceutical compositions for the treatment of cancer

Also Published As

Publication number Publication date
CN112584841A (zh) 2021-03-30
EA202190201A1 (ru) 2021-04-09
BR112021000279A2 (pt) 2021-04-06
PH12021550033A1 (en) 2021-09-20
JP2021530482A (ja) 2021-11-11
KR20220098082A (ko) 2022-07-11
EP3820482A1 (de) 2021-05-19
IL280000A (en) 2021-03-01
EP3820482A4 (de) 2022-03-23
CA3105717A1 (en) 2020-01-30
WO2020023191A1 (en) 2020-01-30
CN112584841A8 (zh) 2021-06-18
BR112021000279A8 (pt) 2021-04-20

Similar Documents

Publication Publication Date Title
EP2970280B1 (de) Verfahren zur behandlung von entzündungen, autoimmunerkrankungen und schmerzen
EP3820482A1 (de) Tumorreduktionsmittelformulierungen und verfahren zur verwendung davon
EP3261646B1 (de) Reduktion von fettgewebe
KR102061486B1 (ko) 에키노칸딘 계열의 화합물에 대한 투여 용법
AU2014340263B2 (en) Tyrosine derivatives and compositions comprising them
JP5919597B2 (ja) デオキシコール酸およびその塩類の製剤
US20210275467A1 (en) Tumor reduction formulations and methods of use thereof
AU2017238817A1 (en) Conjugate vaccine targeting a disease-causing biological protein
JP4807972B2 (ja) 皮膚外用剤
KR102177304B1 (ko) 비알콜성 지방간염의 예방 또는 치료용 약학 조성물
JP6509827B2 (ja) 転移を減少させるまたは阻止するための組成物および方法
US20070207965A1 (en) Method for the treatment of skin fibrosis and suitable compositions for such treatment
EP2240195A1 (de) Melanombehandlung mit alpha-thymosin-peptiden in kombination mit antikörpern gegen mit zytotoxischen t-lymphozyten assoziiertem antigen 4 (ctla4)
TWI510243B (zh) 用於治療膀胱癌的組成物及方法
JP2006505564A (ja) Ｓａｒｍによる高齢男性のアンドロゲン減少に関連する病気の治療
Qin et al. Treatment of liver metastases of human colon cancers in nude mice with somatostatin analogue RC‐160
US11660330B2 (en) Combination therapy with semaphorin-4D blockade (SEMA4D) and DC1 therapy
WO2018164121A1 (ja) 局所麻酔薬含有酸性エマルション組成物
JP2016147890A (ja) デオキシコール酸およびその塩類の製剤
HU230920B1 (hu) Depresszió kezelésére szolgáló androgén gyógyászati készítmények
WO2017120568A1 (en) Apoe mimetic peptide compositions
AU2017414006B2 (en) Use of polypeptide compound in treatment of acute pancreatitis
US20220409552A1 (en) Formulations of terameprocol and temozolomide and their use in stimulation of humoral immunity in tumors
SMELSER et al. The phenomenon of antagonism by pituitary extract in the absence of the thyroid gland
Amoroso et al. Megestrol acetate plus alpha 2a interferon as second line therapy for postmenopausal patients with advanced breast cancer: results of a multicentric phase II trial

Legal Events

Date Code Title Description
DA3 Amendments made section 104

Free format text: THE NATURE OF THE AMENDMENT IS: AMEND THE PRIORITY DETAILS TO READ 62/695,613 09 JUL 2018 US

MK1 Application lapsed section 142(2)(a) - no request for examination in relevant period